Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma.
Adenocarcinoma
/ immunology
Chemotherapy, Adjuvant
Humans
Kaplan-Meier Estimate
Lymphocyte Subsets
/ immunology
Lymphocytes, Tumor-Infiltrating
/ immunology
Pancreas
/ immunology
Pancreatic Neoplasms
/ immunology
Pancreaticoduodenectomy
Prognosis
Retrospective Studies
Spatial Analysis
Survival Rate
Tissue Array Analysis
Tumor Microenvironment
/ immunology
B cells
T cells
lymphocytes
pancreatic cancer
periampullary cancer
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 06 2020
15 06 2020
Historique:
received:
08
11
2019
revised:
15
02
2020
accepted:
21
02
2020
pubmed:
5
3
2020
medline:
9
3
2021
entrez:
5
3
2020
Statut:
ppublish
Résumé
Immunotherapeutic modalities are currently revolutionizing cancer treatment. In pancreatic cancer, however, early clinical trials have been disappointing. The optimization of immunotherapeutic strategies requires better understanding of the inflammatory tumor microenvironment. Therefore, the aim of our study was to perform a detailed in situ description of lymphocyte infiltration patterns in resected pancreatic and other periampullary cancers. Multiplexed immunofluorescence imaging was applied to tissue microarrays with tumors from a cohort of 175 patients with resected periampullary adenocarcinoma. A panel of immune cell markers including CD4, CD8α, FoxP3, CD20, CD45RO and pan-cytokeratin was applied to allow for simultaneous spatial analysis of multiple lymphocyte populations. The majority of lymphocyte populations were significantly more abundant in intestinal (I-type) compared to pancreatobiliary (PB-type) tumors. Hierarchical cluster analysis revealed several immune cell signatures of potential clinical relevance. Notably, in the stromal compartment of PB-type tumors, high infiltration of B cells, CD8α
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3461-3473Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
He C, Mao Y, Wang J, et al. Surgical management of periampullary adenocarcinoma: defining an optimal prognostic lymph node stratification schema. J Cancer 2018;9:1667-79. https://doi.org/10.7150/jca.24109.
Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008;8:170. https://doi.org/10.1186/1471-2407-8-170.
Bronsert P, Kohler I, Werner M, et al. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin. BMC Cancer 2013;13:428. https://doi.org/10.1186/1471-2407-13-428.
Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004;11:223-31. https://doi.org/10.1007/s00534-004-0894-7.
Lundgren S, Hau SO, Elebro J, et al. Mutational landscape in resected Periampullary adenocarcinoma: relationship with morphology and clinical outcome. JCO Precis Oncol 2019;3:1-8. https://doi.org/10.1200/Po.18.00323.
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol 2016;22:9694-705. https://doi.org/10.3748/wjg.v22.i44.9694.
Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet (London, England) 2011;378:607-20. https://doi.org/10.1016/s0140-6736(10)62307-0.
Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. https://doi.org/10.1200/jco.1997.15.6.2403.
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. https://doi.org/10.1056/NEJMoa1011923.
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379:2395-406. https://doi.org/10.1056/NEJMoa1809775.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. https://doi.org/10.1016/j.cell.2011.02.013.
Badalamenti G, Fanale D, Incorvaia L, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol 2018;343:103753. https://doi.org/10.1016/j.cellimm.2018.01.013.
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY) 2006;313:1960-4. https://doi.org/10.1126/science.1129139.
Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-102. https://doi.org/10.1038/onc.2009.416.
Foucher ED, Ghigo C, Chouaib S, et al. Pancreatic ductal adenocarcinoma: a strong imbalance of good and bad immunological cops in the tumor microenvironment. Front Immunol 2018;9:1044. https://doi.org/10.3389/fimmu.2018.01044.
Mahajan UM, Langhoff E, Goni E, et al. Immune cell and stromal signature associated with progression-free survival of patients with resected pancreatic ductal adenocarcinoma. Gastroenterology 2018;155:1625-1639.e2. https://doi.org/10.1053/j.gastro.2018.08.009.
Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015;21:687-92. https://doi.org/10.1158/1078-0432.Ccr-14-1860.
Kabacaoglu D, Ciecielski KJ, Ruess DA, et al. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front Immunol 2018;9:1878. https://doi.org/10.3389/fimmu.2018.01878.
Danilova L, Ho WJ, Zhu Q, et al. Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol Res 2019;7:886-95. https://doi.org/10.1158/2326-6066.Cir-18-0822.
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531:47-52. https://doi.org/10.1038/nature16965.
Stromnes IM, Hulbert A, Pierce RH, et al. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol Res 2017;5:978-91. https://doi.org/10.1158/2326-6066.Cir-16-0322.
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. https://doi.org/10.1038/nature14011.
Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74. https://doi.org/10.1158/1078-0432.Ccr-13-3271.
Elebro J, Jirstrom K. Use of a standardized diagnostic approach improves the prognostic information of histopathologic factors in pancreatic and periampullary adenocarcinoma. Diagn Pathol 2014;9:80. https://doi.org/10.1186/1746-1596-9-80.
Elebro J, Heby M, Warfvinge CF, et al. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in Periampullary adenocarcinoma. PLoS One 2016;11:e0153533. https://doi.org/10.1371/journal.pone.0153533.
Heby M, Lundgren S, Nodin B, et al. Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. J Transl Med 2018;16:66. https://doi.org/10.1186/s12967-018-1444-4.
Elebro J, Heby M, Gaber A, et al. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. J Transl Med 2014;12:289. https://doi.org/10.1186/s12967-014-0289-8.
Heby M, Elebro J, Nodin B, et al. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. BMC Clin Pathol 2015;15:10. https://doi.org/10.1186/s12907-015-0009-1.
Mezheyeuski A, Bergsland CH, Backman M, et al. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. J Pathol 2018;244:421-31. https://doi.org/10.1002/path.5026.
Karanikas V, Speletas M, Zamanakou M, et al. Foxp3 expression in human cancer cells. J Transl Med 2008;6:19. https://doi.org/10.1186/1479-5876-6-19.
Martin F, Ladoire S, Mignot G, et al. Human FOXP3 and cancer. Oncogene 2010;29:4121-9. https://doi.org/10.1038/onc.2010.174.
Carstens JL, de Sampaio PC, Yang D, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 2017;8:15095. https://doi.org/10.1038/ncomms15095.
Kmieciak M, Gowda M, Graham L, et al. Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 2009;7:89. https://doi.org/10.1186/1479-5876-7-89.
Cheng H, Fan K, Luo G, et al. Kras(G12D) mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. Cancer Lett 2019;446:103-11. https://doi.org/10.1016/j.canlet.2019.01.013.
Siemers NO, Holloway JL, Chang H, et al. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS One 2017;12:e0179726. https://doi.org/10.1371/journal.pone.0179726.
Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016;22:813-20. https://doi.org/10.1158/1078-0432.Ccr-15-1678.
Tessier-Cloutier B, Kalloger SE, Al-Kandari M, et al. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer 2017;17:618. https://doi.org/10.1186/s12885-017-3634-5.
Zorro Manrique S, Duque Correa MA, Hoelzinger DB, et al. Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med 2011;208:1485-99. https://doi.org/10.1084/jem.20100730.
Lipscomb MW, Taylor JL, Goldbach CJ, et al. DC expressing transgene Foxp3 are regulatory APC. Eur J Immunol 2010;40:480-93. https://doi.org/10.1002/eji.200939667.
Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911. https://doi.org/10.1016/j.immuni.2009.03.019.
Booth NJ, McQuaid AJ, Sobande T, et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J Immunol 2010;184:4317-26. https://doi.org/10.4049/jimmunol.0903781.
Feichtenbeiner A, Haas M, Buttner M, et al. Critical role of spatial interaction between CD8(+) and Foxp3(+) cells in human gastric cancer: the distance matters. Cancer Immunol Immunother 2014;63:111-9. https://doi.org/10.1007/s00262-013-1491-x.
Barua S, Fang P, Sharma A, et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 2018;117:73-9. https://doi.org/10.1016/j.lungcan.2018.01.022.
Wartenberg M, Cibin S, Zlobec I, et al. Integrated genomic and Immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance. Clin Cancer Res 2018;24:4444-54. https://doi.org/10.1158/1078-0432.Ccr-17-3401.
Schwen LO, Andersson E, Korski K, et al. Data-driven discovery of immune contexture biomarkers. Front Oncol 2018;8:627. https://doi.org/10.3389/fonc.2018.00627.
Barua S, Solis L, Parra ER, et al. A functional spatial analysis platform for discovery of immunological interactions predictive of low-grade to high-grade transition of pancreatic Intraductal papillary mucinous neoplasms. Cancer informatics 2018;17:1176935118782880. https://doi.org/10.1177/1176935118782880.
Masugi Y, Abe T, Ueno A, et al. Characterization of spatial distribution of tumor-infiltrating CD8(+) T cells refines their prognostic utility for pancreatic cancer survival. Mod Pathol 2019;32:1495-507. https://doi.org/10.1038/s41379-019-0291-z.
Giuntoli RL 2nd, Lu J, Kobayashi H, et al. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002;8:922-31.
Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010;70:8368-77. https://doi.org/10.1158/0008-5472.Can-10-1322.
Bos R, Marquardt KL, Cheung J, et al. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology 2012;1:1239-47. https://doi.org/10.4161/onci.21285.
Schietinger A, Philip M, Liu RB, et al. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 2010;207:2469-77. https://doi.org/10.1084/jem.20092450.